*4.3. Immunosuppressive Drugs, Rejection and Rejection Treatment*

All patients received immunosuppressive drug therapy according to the standard of care at the time of transplantation. IL-2 receptor inhibitor as induction therapy was the standard of care and alemtuzumab was administered in case the treating physician expected a higher risk of rejection. The presence and type of rejection was assessed using the Banff classification. The choice for a specific rejection treatment was made according to the standard of care at the time of rejection [13].
